Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum Sensitive Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04361370
What this trial is testing

Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer
Yonsei University 44
Testing effectiveness (Phase 2)Study completedNCT02759588
What this trial is testing

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CarcinomatosisFallopian Tube Cancer
Genelux Corporation 46
Testing effectiveness (Phase 2)Ended earlyNCT00758732
What this trial is testing

Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma

Who this might be right for
Ovarian Cancer
Hellenic Oncology Research Group 34
Testing effectiveness (Phase 2)Study completedNCT00719212
What this trial is testing

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Translational Research in Oncology 61
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06081595
What this trial is testing

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Who this might be right for
Relapsed Ovarian Cancer
Jin Li 54
Testing effectiveness (Phase 2)Ended earlyNCT00091195
What this trial is testing

Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer

Who this might be right for
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
National Cancer Institute (NCI) 51
Large-scale testing (Phase 3)Looking for participantsNCT06824467
What this trial is testing

Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Merck Sharp & Dohme LLC 770
Testing effectiveness (Phase 2)Study completedNCT02953457
What this trial is testing

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationOvarian Serous Adenocarcinoma+3 more
Roswell Park Cancer Institute 40
Testing effectiveness (Phase 2)Study completedNCT00780039
What this trial is testing

Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

Who this might be right for
Ovarian Neoplasms
Merck Sharp & Dohme LLC 58
Early research (Phase 1)Study completedNCT00002600
What this trial is testing

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 23
Not applicableUnknownNCT05069818
What this trial is testing

Variance of HRD From Paired Ovarian Cancer

Who this might be right for
Ovarian CancerHRDPlatinum-sensitive Ovarian Cancer
Xiaoxiang Chen 50
Testing effectiveness (Phase 2)Study completedNCT00004083
What this trial is testing

Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
NYU Langone Health
Not applicableStudy completedNCT02394015
What this trial is testing

Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC

Who this might be right for
Ovarian Epithelial Cancer Recurrent
Grupo Español de Investigación en Cáncer de Ovario 90
Testing effectiveness (Phase 2)Study completedNCT00698451
What this trial is testing

Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Who this might be right for
Ovarian NeoplasmsFallopian Tube NeoplasmsPeritoneal Neoplasms
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 54
Testing effectiveness (Phase 2)UnknownNCT01600573
What this trial is testing

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Who this might be right for
Ovarian Cancer
JSehouli 68
Large-scale testing (Phase 3)Study completedNCT01968213
What this trial is testing

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
pharmaand GmbH 564
Large-scale testing (Phase 3)Study completedNCT00434642
What this trial is testing

Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma

Who this might be right for
Ovarian Cancer
Genentech, Inc. 484
Testing effectiveness (Phase 2)Study completedNCT00466986
What this trial is testing

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Southeastern Gynecologic Oncology 40
Large-scale testing (Phase 3)Ended earlyNCT05329545
What this trial is testing

Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

Who this might be right for
High Grade Serous Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Mersana Therapeutics 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04034927
What this trial is testing

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid Tumor+11 more
National Cancer Institute (NCI) 61
Next Page